Business
Cyclerion Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
- IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively - - Completed $24 million equity
About this update from Cyclerion Therapeutics, Inc.
[{"type":"text","content":"- IW-6463 and olinciguat top line clinical study results remain on track for late summer and late Q3 2020, respectively -\n - Completed $24 million equity private placement to accelerate clinical development of IW-6463 for the CNS diseases MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) and ADv (Alzheimer's Disease with Vascular pathology) and of olinciguat for sickle cell disease - - CNS focused webcast event held to highlight IW-6463 development plan and opportunity to address serious CNS diseases CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, reported financial results for the second quarter ended June 30, 2020 and provided general corporate and pipeline updates. “We are looking forward to upcoming top line results from both our translational pharmacology study for IW-6463, the first brain-penetrant sGC stimulator to enter clinical development, and our STRONG olinciguat Phase 2 study for sickle cell disease. Both programs have the potential to provide a fundamentally new approach for patients with limited therapeutic options today”, said Peter Hecht, Ph.D., Chief Executive Officer of Cyclerion. Recent Program and Business Updates IW-6463 Program Update: Top line data from the translational pharmacology study of IW-6463, the company’s investigational, orally administered, once-daily CNS-penetrant sGC stimulator designed for the treatment of two serious CNS diseases are expected in late summer 2020. Each of these indications harness the multi-dimensional pharmacology of the as-yet untapped nitric oxide neurotransmitter system.On July 9th, Cyclerion hosted a webcast focused on IW-6463, during which Cyclerion clinical and scientific leaders and external subject matter experts discussed IW-6463 preclinical and Phase 1 clinical study data, design of the ongoing IW-6463 translational pharmacology clinical study, and anticipated development directions into Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv). In the session, the company described the potential impact on MELAS, a genetically defined disease for which there is no approved treatment, by addressing multiple asp...